Lipid-based carriers for pulmonary products: Preclinical development and case studies in humans

Advanced Drug Delivery Reviews

Volumn 75, Issue , 2014, Pages 53-80

  Cipolla, David ^a   Shekunov, Boris ^b   Blanchard, Jim ^a   Hickey, Anthony ^c  

^a ARADIGM CORPORATION   (United States)

^b SHIRE   (United States)

^c RTI INTERNATIONAL   (United States)

Author keywords

Lipid microparticles; Liposomes; Nanostructured lipid carriers; Pulmonary delivery; Solid lipid nanoparticles

Indexed keywords

DRUG PRODUCTS; LIPOSOMES; NANOPARTICLES; TARGETED DRUG DELIVERY;

DRUG RELEASE; LIPID MICROPARTICLES; MANUFACTURING PROCESS; NANOSTRUCTURED LIPID CARRIERS; POORLY SOLUBLE DRUGS; PRECLINICAL DEVELOPMENT; PULMONARY DELIVERY; SOLID LIPID NANOPARTICLE (SLN);

CONTROLLED DRUG DELIVERY;

AMIKACIN; BUDESONIDE; CIPROFLOXACIN; CROMOGLYCATE DISODIUM; DRUG CARRIER; FORMOTEROL; INSULIN; LIPOSOME; PHOSPHATIDYLCHOLINE; PLACEBO; RESPIRATORY TRACT AGENT; SALBUTAMOL; SOLID LIPID NANOPARTICLE; SOLUTOL HS 15; TOBRAMYCIN; LIPID; NANOMATERIAL;

ASTHMA; BRONCHITIS; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COUGHING; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER INHALER; DYSGEUSIA; DYSPHONIA; DYSPNEA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEARING IMPAIRMENT; HUMAN; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; LARYNGITIS; LIPOSOMAL DELIVERY; LUNG DISEASE; LUNG FUNCTION; LUNG HEMORRHAGE; MEDIASTINUM DISEASE; MEDICAL NEBULIZER; MIGRAINE; MULTIPLE CYCLE TREATMENT; NANOEMULSION; NANOENGINEERING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; REVIEW; SORE THROAT; STRUCTURE ANALYSIS; THORAX DISEASE; TINNITUS; ANIMAL; CHEMISTRY; DRUG SCREENING; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM;

ADMINISTRATION, INHALATION; ANIMALS; DRUG CARRIERS; DRUG EVALUATION, PRECLINICAL; HUMANS; LIPIDS; LUNG; NANOSTRUCTURES;

EID: 84908226561     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.05.001     Document Type: Review

References (335)

1. Dalby R.N., Tiano S.L., Hickey A.J. Medical devices for the delivery of therapeutic aerosols to the lungs. Inhalation Aerosols: Physical and Biological Basis for Therapy 1996, 441-473. Marcel Dekkar, Inc., New York. A.J. Hickey (Ed.).
2. Weers J.G., Bell J., Chan H.K., Cipolla D., Dunbar C., Hickey A.J., Smith I.J. Pulmonary formulations: what remains to be done?. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23(Suppl. 2):S5-S23.
3. Cipolla D., Chan H.K., Schuster J.K., Farina D. Personalizing aerosol medicine: development of delivery systems tailored to the individual. Ther. Deliv. 2010, 1:667-682.
4. Cipolla D., Gonda I. Formulation technology to repurpose drugs for inhalation delivery. Drug Discov. Today 2011, 8:123-130.
5. Seville P.C., Li H.Y., Learoyd T.P. Spray-dried powders for pulmonary drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 2007, 24:307-360.
6. Cipolla D., Chan H.K. Inhaled antibiotics to treat lung infection. Pharm. Patent Anal. 2013, 2:647-663.
7. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., Mintzes J., Deaver D., Lotan N., Langer R. Large porous particles for pulmonary drug delivery. Science 1997, 276:1868-1871.
8. Cipolla D., Gonda I., Chan H.-K. Liposomal formulations for inhalation. Ther. Deliv. 2013, 4:1047-1072.
9. Weber S., Zimmer A., Pardeike J. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art. Eur. J. Pharm. Biopharm. 2014, 86:7-22. 10.1016/j.ejpb.2013.08.013.
10. Bivas-Benita M., Oudshoorn M., Romeijn S., van Meijgaarden K., Koerten H., van der Meulen H., Lambert G., Ottenhoff T., Benita S., Junginger H., Borchard G. Cationic submicron emulsions for pulmonary DNA immunization. J. Control. Release 2004, 100:145-155.
11. Dunbar C., Scheuch G., Sommerer K., DeLong M., Verma A., Batycky R. In vitro and in vivo dose delivery characteristics of large porous particles for inhalation. Int. J. Pharm. 2002, 245:179-189.
12. Dellamary L.A., Tarara T.E., Smith D.J., Woelk C.H., Adractas A., Costello M.L., Gill H., Weers J.G. Hollow porous particles in metered dose inhalers. Pharm. Res. 2000, 17:168-174.
13. Crowder T.M., Rosati J.A., Schroeter J.D., Hickey A.J., Martonen T.B. Fundamental effects of particle morphology on lung delivery: predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm. Res. 2002, 19:239-245.
14. Ganderton D., Hickey A.J. Size reduction and classification in Pharmaceutical Process Engineering 2000, 136-154. Informa Healthcare, New York. second ed.
15. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm. Res. 2008, 25:999-1022.
16. Crowder T.M., Hickey A.J., Louey M.D., Orr N. A Guide to Pharmaceutical Particulate Science 2003, 86-103. Interpharm/CRC, Boca Raton, FL.
17. Evans J., McCormick R.F., Morishige D., Olson S.N., Weers B., Hilley J., Klein P., Rooney W., Mullet J. Fundamentals of Interfacial Engineering 1997, 34-43. Wiley-VCH, New York.
18. Israelachvili J. Intermolecular and Surface Forces 1992, 83-108. Academic Press, New York.
19. Chow A.H., Tong H.H., Chattopadhyay P., Shekunov B.Y. Particle engineering for pulmonary drug delivery. Pharm. Res. 2007, 24:411-437.
20. B.Y. Shekunov, Production of powders for respiratory drug delivery, in: P. York, U.B. Kompella, B.Y. Shekunov (eds.) Supercritical Fluid Technology for Drug Product Development, Marcel Dekker: New York. pp. 247-282.
21. Weers J., Tarara T. The PulmoSphere platform for pulmonary drug delivery. Ther. Deliv. 2014, 5:277-295.
22. Ungaro F., Giovani C., Coletta C., Sorrentino R., Miro A., Quaglia F. Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung. Eur. J. Pharm. Sci. 2010, 41:60-70.
23. Ben-Jebria A., Chen D., Eskew M.L., Vanbever R., Langer R., Edwards D.A. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm. Res. 1999, 16:555-561.
24. Bosquillon C., Lombry C., Preat V., Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Release 2001, 70:329-339.
25. Vanbever R., Mintzes J.D., Wang J., Nice J., Chen D., Batycky R., Langer R., Edwards D.A. Formulation and physical characterization of large porous particles for inhalation. Pharm. Res. 1999, 16:1735-1742.
26. Wang J., Ben-Jebria A., Edwards D.A. Inhalation of estradiol for sustained systemic delivery. J. Aerosol Med. 1999, 12:27-36.
27. Codrons V., Vanderbist F., Verbeeck R.K., Arras M., Lison D., Preat V., Vanbever R. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J. Pharm. Sci. 2003, 92:938-950.
28. Codrons V., Vanderbist F., Ucakar B., Preat V., Vanbever R. Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J. Pharm. Sci. 2004, 93:1241-1252.
29. Bosquillon C., Preat V., Vanbever R. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J. Control. Release 2004, 96:233-244.
30. Dellamary L., Smith D.J., Bloom A., Bot S., Guo G.R., Deshmuk H., Costello M., Bot A. Rational design of solid aerosols for immunoglobulin delivery by modulation of aerodynamic and release characteristics. J. Control. Release 2004, 95:489-500.
31. Steckel H., Brandes H.G. A novel spray-drying technique to produce low density particles for pulmonary delivery. Int. J. Pharm. 2004, 278:187-195.
32. Sebti T., Amighi K. Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation. Eur. J. Pharm. Biopharm. 2006, 63:51-58.
33. Sebti T., Oilcer G., Van Gansbaeke B., Goldman S., Michils A., Vanderbist F., Amighi K. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation. Eur. J. Pharm. Biopharm. 2006, 64:26-32.
34. Weers J.G., Tarara T., Malcolmson R., Leung D. Embedded crystals in low density particles: formulation, manufacture, and properties. Respiratory Drug Delivery 2006 2006, 297-306. Davis Healthcare LLC, River Grove, IL. P.R. Byron, R.N. Dalby, J. Peart, J.D. Suman, S.J. Farr, P.M. Young (Eds.).
35. Minne A., Boireau H., Horta M.J., Vanbever R. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients. Eur. J. Pharm. Biopharm. 2008, 70:839-844.
36. Lechuga-Ballesteros D., R.V., Dwivedi Sarvajna K. A new co-suspension MDI platform: scientific foundations of mono, dual and triple combination products. RDD Europe 2011 2011, 101-112. Davis Healthcare Int'l Publishing, IL. P.R. Byron, R.N. Dalby, J. Peart, J.D. Suman, S.J. Farr, P.M. Young (Eds.).
37. Bot A.I., Tarara T.E., Smith D.J., Bot S.R., Woods C.M., Weers J.G. Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm. Res. 2000, 17:275-283.
38. Newhouse M.T., Hirst P.H., Duddu S.P., Walter Y.H., Tarara T.E., Clark A.R., Weers J.G. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003, 124:360-366.
39. Tarara T.E., Weers J.G., Dellamary L.A. Engineered powders for inhalation. Respiratory Drug Delivery VIII 2000, 413-416. Amy Davis, Raleigh, NC. P.R. Byron, R.N. Dalby, S.J. Farr, J. Peart (Eds.).
40. Bot A., Smith D., Tarara T.E., Harders S., Bot S., Langsetmo I., Woods C., Weers J.G. Vaccination by antigen delivery to airway antigen presenting cells via engineered, lipid-based microparticles. Respiratory Drug Delivery VII 2000, 327-328. Amy Davis, Raleigh, NC. P.R. Byron, R.N. Dalby, S.J. Farr, J. Peart (Eds.).
41. Hirst P.H., Pitcairn G.R., Weers J.G., Tarara T.E., Clark A.R., Dellamary L.A., Hall G., Shorr J., Newman S.P. In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler. Pharm. Res. 2002, 19:258-264.
42. Bot A.I., Smith D.J., Bot S., Dellamary L., Tarara T.E., Harders S., Phillips W., Weers J.G., Woods C.M. Receptor-mediated targeting of spray-dried lipid particles coformulated with immunoglobulin and loaded with a prototype vaccine. Pharm. Res. 2001, 18:971-979.
43. Smith D.J., Gambone L.M., Tarara T., Meays D.R., Dellamary L.A., Woods C.M., Weers J. Liquid dose pulmonary instillation of gentamicin PulmoSpheres formulations: tissue distribution and pharmacokinetics in rabbits. Pharm. Res. 2001, 18:1556-1561.
44. Duddu S.P., Sisk S.A., Walter Y.H., Tarara T.E., Trimble K.R., Clark A.R., Eldon M.A., Elton R.C., Pickford M., Hirst P.H., Newman S.P., Weers J.G. Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder. Pharm. Res. 2002, 19:689-695.
45. Pilcer G., Sebti T., Amighi K. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm. Res. 2006, 23:931-940.
46. Geller D.E., Weers J., Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J. Aerosol. Med. Pulm. Drug Deliv. 2011, 24:175-182.
47. Depreter F., Burniat A., Blocklet D., Lacroix S., Cnop M., Fery F., Aelst N.V., Pilcer G., Deleers M., Goldman S., Amighi K. Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients. Eur. J. Pharm. Biopharm. 2012, 80:4-13.
48. Depreter F., Amighi K. Formulation and in vitro evaluation of highly dispersive insulin dry powder formulations for lung administration. Eur. J. Pharm. Biopharm. 2010, 76:454-463.
49. Mezzena M., Scalia S., Young P.M., Traini D. Solid lipid budesonide microparticles for controlled release inhalation therapy. AAPS J. 2009, 11:771-778.
50. Sanna V., Kirschvink N., Gustin P., Gavini E., Roland I., Delattre L., Evrard B. Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration. AAPS PharmSciTech 2004, 5:e27.
51. Scalia S., SAlama R., Young P., Traini D. Preparation and in vitro evaluation of salbutamol-loaded lipid microparticles for sustained release pulmonary therapy. J. Microencapsul. 2012, 29:225-233.
52. Scalia S., Haghi M., Losi V., Trotta V., Young P.M., Traini D. Quercetin solid lipid microparticles: a flavonoid for inhalation lung delivery. Eur. J. Pharm. Sci. 2013, 49:278-285.
53. Burgess D.J., Hickey A.J. Encyclopedia of Pharmaceutical Technology 1996, 1-29. Marcel Dekker Inc, New York.
54. van Oort M.M., Sacchetti M. Spray drying and supercritical fluid particle generation techniques. Inhalation Aerosols, Physical and Biological Basis for Therapy 2007, 307-346. Informa Healthcare, New York. A.J. Hickey (Ed.).
55. Rosenstock J., Muchmore D., Swanson D., Schmitke J. AIR Inhaled Insulin System: a novel insulin-delivery system for patients with diabetes. Expert Rev. Med. Devices 2007, 4:683-692.
56. Stass H., Baumann-Noss H., Delesen J., Nagelschmitz J., Willmann S., Edginton A., Staab D. Pharmacokinetics of ciprofloxacin PulmoSphere inhalation powder. J. Cyst. Fibros. 2008, 7:S26. (Suppl.).
57. Edwards D.A., Ben-Jebria A., Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J. Appl. Physiol. 1998, 85:379-385.
58. Walvoord E.C., de la Pena A., Park S., Silverman B., Cuttler L., Rose S.R., Cutler G., Drop S., Chipman J.J. Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharmacokinetics, pharmacodynamics, and safety. J. Clin. Endocrinol. Metab. 2009, 94:2052-2059.
59. Konstan M.W., VanDevanter D.R., Rasouliyan L., Pasta D.J., Yegin A., Morgan W.J., Wagener J.S. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr. Pulmonol. 2010, 45:1167-1172.
60. Konstan M.W., Flume P.A., Kappler M., Chiron R., Higgins M., Brockhaus F., Zhang J., Angyalosi G., He E., Geller D.E. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J. Cyst. Fibros. 2011, 10:54-61.
61. DeLong M., Wright J., Dawson M., Meyer T., Sommerer K., Dunbar C. Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates. J. Aerosol Med. 2005, 18:452-459.
62. Zarogoulidis P., Papanas N., Kouliatis G., Spyratos D., Zarogoulidis K., Maltezos E. Inhaled insulin: too soon to be forgotten?. J. Aerosol. Med. Pulm. Drug Deliv. 2011, 24:213-223.
63. Muchmore D.B., Silverman B., De La Pena A., Tobian J. The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol. Ther. 2007, 9:S41-S47.
64. Silverman B.L., Barnes C.J., Campaigne B.N., Muchmore D.B. Inhaled insulin for controlling blood glucose in patients with diabetes. Vasc. Health Risk Manag. 2007, 3:947-958.
65. de la Pena A., Seger M., Rave K., Heinemann L., Silverman B., Muchmore D.B. AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamics. Diabetes Technol. Ther. 2009, 11:S75-S80.
66. Rave K., Bott S., Heinemann L., Sha S., Becker R.H., Willavize S.A., Heise T. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005, 28:1077-1082.
67. Rave K.M., Nosek L., de la Pena A., Seger M., Ernest C.S., Heinemann L., Batycky R.P., Muchmore D.B. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care 2005, 28:2400-2405.
68. Comulada A.L., Renard E., Nakano M., Rais N., Mao X., Webb D.M., Milicevic Z. Efficacy and safety of AIR inhaled insulin compared to insulin lispro in patients with type 1 diabetes mellitus in a 6-month, randomized, noninferiority trial. Diabetes Technol. Ther. 2009, 11:S17-S25.
69. Garg S.K., Mathieu C., Rais N., Gao H., Tobian J.A., Gates J.R., Ferguson J.A., Webb D.M., Berclaz P.Y. Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: an open-label randomized controlled trial. Diabetes Technol. Ther. 2009, 11:S5-S16.
70. Ang E., Heilmann C.R., Ferguson J.A., Tobian J.A., Webb D.M., Berclaz P.Y. Safety and efficacy of AIR inhaled insulin compared with subcutaneous insulin in patients having diabetes and asthma: a 12-month, randomized, noninferiority trial. Diabetes Technol. Ther. 2009, 11:S35-S44.
71. Wolzt M., de la Pena A., Berclaz P.Y., Tibaldi F.S., Gates J.R., Muchmore D.B. AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. Diabetes Care 2008, 31:735-740.
72. Garg S., Rosenstock J., Silverman B.L., Sun B., Konkoy C.S., de la Pena A., Muchmore D.B. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 2006, 49:891-899.
73. Gross J.L., Nakano M., Colon-Vega G., Ortiz-Carasquillo R., Ferguson J.A., Althouse S., Tobian J.A., Berclaz P.Y., Milicevic Z. Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: a randomized noninferiority trial. Diabetes Technol. Ther. 2009, 11:S27-S34.
74. Rosenstock J., Eliaschewitz F.G., Heilmann C.R., Muchmore D.B., Hayes R.P., Belin R.M. Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine. Diabetes Technol. Ther. 2009, 11:S63-S73.
75. Rave K., de la Pena A., Tibaldi F.S., Zhang L., Silverman B., Hausmann M., Heinemann L., Muchmore D.B. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. Diabetes Care 2007, 30:1777-1782.
76. Rosenstock J., Cefalu W.T., Hollander P.A., Belanger A., Eliaschewitz F.G., Gross J.L., Klioze S.S., St Aubin L.B., Foyt H., Ogawa M., Duggan W.T. Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes. Diabetes Care 2008, 31:1723-1728.
77. Rosenstock J., Cefalu W.T., Hollander P.A., Klioze S.S., Reis J., Duggan W.T. Safety and efficacy of inhaled human insulin (exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial. Diabetes Technol. Ther. 2009, 11:697-705.
78. Skyler J.S., Hollander P.A., Jovanovic L., Kliose S., Krasner A., Riese R.J., Reis J., Schwartz P., Duggan W. Safety and efficacy of inhaled human insulin (Exubera) during discontinuation and readministration of therapy in adults with type 1 diabetes: a 3-year randomized controlled trial. Diabetes Res. Clin. Pract. 2008, 82:238-246.
79. Skyler J.S., Jovanovic L., Kliose S., Reis J., Duggan W. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 2007, 30:579-585.
80. Lange P., Parner J., Schnohr P., Jensen G. Copenhagen City Heart Study: longitudinal analysis of ventilatory capacity in diabetic and nondiabetic adults. Eur. Respir. J. 2002, 20:1406-1412.
81. Kaparianos A., Argyropoulou E., Sampsonas F., Karkoulias K., Tsiamita M., Spiropoulos K. Pulmonary complications in diabetes mellitus. Chron. Respir. Dis. 2008, 5:101-108.
82. McKeever T.M., Weston P.J., Hubbard R., Fogarty A. Lung function and glucose metabolism: an analysis of data from the Third National Health and Nutrition Examination Survey. Am. J. Epidemiol. 2005, 161:546-556.
83. Duncan B.B., Schmidt M.I., Pankow J.S., Ballantyne C.M., Couper D., Vigo A., Hoogeveen R., Folsom A.R., Heiss G. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003, 52:1799-1805.
84. Schaafsma D., Gosens R., Ris J.M., Zaagsma J., Meurs H., Nelemans S.A. Insulin induces airway smooth muscle contraction. Br. J. Pharmacol. 2007, 150:136-142.
85. Schaafsma D., McNeil K.D., Stelmack G.L., Gosens R., Baarsma H.A., Dekkars B.G., Frohwerk E., Penninks J.M., Sharma P., Ens K.M., Nelemans S.A., Zaagsma J., Halayko A.J., Meurs H. Insulin increases the expression of contractile phenotypic markers in airway smooth muscle. Am. J. Physiol. Cell Physiol. 2007, 293:C429-C439.
86. Dekkers B.G., Schaafsma D., Tran T., Zaagsma J., Meurs H. Insulin-induced laminin expression promotes a hypercontractile airway smooth muscle phenotype. Am. J. Respir. Cell Mol. Biol. 2009, 41:494-504.
87. Konstan M.W., Geller D.E., Minic P., Brockhaus F., Zhang J., Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr. Pulmonol. 2011, 46:230-238.
88. Galeva I., Konstan M.W., Higgins M., Angyalosi G., Brockhaus F., Piggott S., Thomas K., Chuchalin A.G. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Curr. Med. Res. Opin. 2013, 29:947-956.
89. Maiz L., Giron R.M., Olveira C., Quintana E., Lamas A., Pastor D., Canton R., Mensa J. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials. Expert. Opin. Pharmacother. 2013, 14:1135-1149.
90. Antoniu S., Azoicai D. Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opin. Investig. Drugs 2013, 22:671-673.
91. Serisier D.J. Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin. Drugs Today 2012, 48:339-351.
92. Wilson R., Welte T., Polverino E., DeSoyza A., Greville H., O'Donnell A., Alder J., Reimnitz P., Hampel B. Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur. Respir. J. 2013, 41:1107-1115.
93. Stass H., Nagelschmitz J., Willmann S., Delesen H., Gupta A., Baumann S. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. Clin. Drug Investig. 2013, 33:419-427.
94. Doring G., Flume P., Heijerman H., Elborn J.S. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cyst. Fibros. 2012, 11:461-479.
95. Vehring R., Lechuga-Ballesteros D., Joshi V., Noga B., Dwivedi S.K. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir 2012, 28:15015-15023.
96. Bangham A.D. Lipid bilayers and biomembranes. Annu. Rev. Biochem. 1972, 41:753-776.
97. Bangham A.D., Horne R.W. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J. Mol. Biol. 1964, 8:660-668.
98. Ong H.X., Benaouda F., Traini D., Cipolla D., Gonda I., Bebawy M., Forbes B., Young P.M. In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. Eur. J. Pharm. Biopharm. 2014, 86:83-89.
99. Ong H.X., Traini D., Cipolla D., Gonda I., Bebawy M., Agus H., Young P.M. Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. Pharm. Res. 2012, 29:3335-3346.
100. Farr S.J., Kellaway I.W., Carman-Meakin B. Assessing the potential of aerosol-generated liposomes from pressurised pack formulations. J. Control. Release 1987, 5:119-127.
101. Wyde P.R., Six H.R., Wilson S.Z., Gilbert B.E., Knight V. Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes. Antimicrob. Agents Chemother. 1988, 32:890-895.
102. Gilbert B.E., Six H.R., Wilson S.Z., Wyde P.R., Knight V. Small particle aerosols of enviroxime-containing liposomes. Antivir. Res. 1988, 9:355-365.
103. Gilbert B.E., Wyde P.R., Wilson S.Z. Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice. Antimicrob. Agents Chemother. 1992, 36:1466-1471.
104. Gilbert B.E., Wilson S.Z., Garcon N.M., Wyde P.R., Knight V. Characterization and administration of cyclosporine liposomes as a small-particle aerosol. Transplantation 1993, 56:974-977.
105. Gilbert B.E., Wyde P.R., Lopez-Berestein G., Wilson S.Z. Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice. Antimicrob. Agents Chemother. 1994, 38:356-359.
106. Leung K.K.M., Bridges P.A., Taylor K.M.G. The stability of liposomes to ultrasonic nebulisation. Int. J. Pharm. 1996, 145:95-102.
107. Chono S., Fukuchi R., Seki T., Morimoto K. Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. J. Control. Release 2009, 137:104-109.
108. Madden T.D., Bally M.B., Hope M.J., Cullis P.R., Schieren H.P., Janoff A.S. Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim. Biophys. Acta 1985, 817:67-74.
109. Strauss G., Schurtenberger P., Hauser H. The interaction of saccharides with lipid bilayer vesicles: stabilization during freeze-thawing and freeze-drying. Biochim. Biophys. Acta 1986, 858:169-180.
110. Bridges P.A., Taylor K.M. The effects of freeze-drying on the stability of liposomes to jet nebulization. J. Pharm. Pharmacol. 2001, 53:393-398.
111. Thomas D.A., Myers M.A., Wichert B., Schreier H., Gonzalez-Rothi R.J. Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers. Chest 1991, 99:1268-1270.
112. Goldbach P., Brochart H., Stamm A. Spray-drying of liposomes for a pulmonary administration. I. Chemical stability of phospholipids. Drug Dev. Ind. Pharm. 1993, 19:2611-2622.
113. Goldbach P., Brochart H., Stamm A. Spray-drying of liposomes for a pulmonary administration. II. Retention of encapsulated materials. Drug Dev. Ind. Pharm. 1993, 19:2623-2636.
114. Parmar J.J., Singh D.J., Lohade A.A., Hegde D.D., Soni P.S., Samad A., Menon M.D. Inhalational system for etoposide liposomes: formulation development and in vitro deposition. Indian J. Pharm. Sci. 2011, 73:656-662.
115. Myers M.A., Thomas D.A., Straub L., Soucy D.W., Niven R.W., Kaltenbach M., Hood C.I., Schreier H., Gonzalez-Rothi R.J. Pulmonary effects of chronic exposure to liposome aerosols in mice. Exp. Lung Res. 1993, 19:1-19.
116. Darwis Y., Kellaway I.W. Nebulisation of rehydrated freeze-dried beclomethasone dipropionate liposomes. Int. J. Pharm. 2001, 215:113-121.
117. Robillard E., Alarie Y., Dagenais-Perusse P., Bari E., Guibeault A. Microaerosol administration of synthetic beta-gamma-diapalmitoyl-l-alpha-lecithin in the respiratory distress syndrome: a preliminary report. Can. Med. Assoc. J. 1964, 90:55-57.
118. Farr S.J., Kellaway I.W., Parry-Jones D.R., Woolfrey S.G. 99m-Technetium as a marker of liposomal deposition and clearance in the human lung. Int. J. Pharm. 1985, 26:303-316.
119. Suntres Z.E., Shek P.N. Incorporation of alpha-tocopherol in liposomes promotes the retention of liposome-encapsulated glutathione in the rat lung. J. Pharm. Pharmacol. 1994, 46:23-28.
120. Saari M., Vidgren M.T., Koskinen M.O., Turjanmaa V.M., Nieminen M.M. Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers. Int. J. Pharm. 1999, 181:1-9.
121. Suntres Z.E., Shek P.N. Alleviation of paraquat-induced lung injury by pretreatment with bifunctional liposomes containing alpha-tocopherol and glutathione. Biochem. Pharmacol. 1996, 52:1515-1520.
122. Abu-Dahab R., Schafer U.F., Lehr C.M. Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion. Eur. J. Pharm. Sci. 2001, 14:37-46.
123. Lange C.F., Hancock R.E., Samuel J., Finlay W.H. In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide. J. Pharm. Sci. 2001, 90:1647-1657.
124. Desai T.R., Hancock R.E., Finlay W.H. A facile method of delivery of liposomes by nebulization. J. Control. Release 2002, 84:69-78.
125. Waldrep J.C., Keyhani K., Black M., Knight V. Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol. Chest 1994, 105:106-110.
126. 99mtechnetium-labelled beclomethasone dipropionate dilauroylphosphatidylcholine liposome aerosol in normal volunteers. Int. J. Pharm. 1995, 115:209-216.
127. Berlinski A., Waldrep J.C. Effect of aerosol delivery system and formulation on nebulized budesonide output. J. Aerosol Med. 1997, 10:307-318.
128. Gilbert B.E., Knight C., Alvarez F.G., Waldrep C., Rodarte J.R., Knight V., Eschenbacher W.L. Tolerance of volunteers to cyclosporine A-dilauroylphosphatidylcholine liposome aerosol. Am. J. Respir. Crit. Care Med. 1997, 156:1789-1793.
129. Gilbert B.E., Black M.B., Waldrep J.C., Montgomery J.B.C., Knight V. Cyclosporin A liposome aerosol: lack of acute toxicity in rats with a high incidence of udnerlying pneumonitis. Inhal. Toxicol. 1997, 9:717-730.
130. Waldrep J.C., Gilbert B.E., Knight C.M., Black M.B., Scherer P.W., Knight V., Eschenbacher W. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance and safety. CHEST 1997, 111:316-323.
131. Waldrep J.C., Arppe J., Jansa K.A., Vidgren M. Experimental pulmonary delivery of cyclosporin A by liposome aerosol. Int. J. Pharm. 1998, 160:239-249.
132. 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma. Chest 1998, 113:1573-1579.
133. Koshkina N.V., Gilbert B.E., Waldrep J.C., Seryshev A., Knight V. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother. Pharmacol. 1993, 44:187-192.
134. Knight V., Koshkina N., Waldrep C., Giovanella B.C., Kleinerman E., Gilbert B. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother. Pharmacol. 1999, 44:177-186.
135. Letsou G.V., Safi H.J., Reardon M.J., Ergenoglu M., Li Z., Klonaris C.N., Baldwin J.C., Gilbert B.E., Waldrep J.C. Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. Ann. Thorac. Surg. 1999, 68:2044-2048.
136. Koshkina N.V., et al. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin. Cancer Res. 2000, 6(7):2876-2880.
137. Knight V., Kleinerman E.S., Waldrep J.C., Giovanella B.C., Gilbert B.E., Koshkina N.V. 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Ann. N. Y. Acad. Sci. 2000, 922:151-163.
138. Gilbert B.E., Seryshev A., Knight V., Brayton C. 9-nitrocamptothecin liposome aerosol: lack of subacute toxicity in dogs. Inhal. Toxicol. 2002, 14:185-197.
139. Saari S.M., Vidgren M.T., Herrala J., Turjanmaa V.M., Koskinen M.O., Nieminen M.M. Possibilities of formoterol to enhance the peripheral lung deposition of the inhaled liposome corticosteroids. Respir. Med. 2002, 96:999-1005.
140. Verschraegen C.F., Gilbert B.E., Loyer E., Huaringa A., Walsh G., Newman R.A., Knight V. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin. Cancer Res. 2004, 10:2319-2326.
141. Koshkina N.V., Golunski E., Roberts L.E., Gilbert B.E., Knight V. Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J. Aerosol Med. 2004, 17:7-14.
142. Latimer P., Menchaca M., Snyder R.M., Yu W., Gilbert B.E., Sanders B.G., Kline K. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases. Exp. Biol. Med. 2009, 234:1244-1252.
143. Khanna C., Waldrep J.C., Anderson P.M., Weischelbaum R.W., Hasz D.E., Katsanis E., Klausner J.S. Nebulized interleukin 2 liposomes: aerosol characteristics and biodistribution. J. Pharm. Pharmacol. 1997, 49:960-971.
144. Ten R.M., Anderson P.M., Zien N.N., Temesgen Z., Clawson M.L., Weiss W. Interleukin-2 liposomes for primary immune deficiency using the aerosol route. Int. Immunopharmacol. 2002, 2:333-344.
145. Desai T.R., Hancock R.E., Finlay W.H. Delivery of liposomes in dry powder form: aerodynamic dispersion properties. Eur. J. Pharm. Sci. 2003, 20:459-467.
146. Wallace S.J., Nation R.L., Li J., Boyd B.J. Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies. J. Pharm. Sci. 2013, 102:1578-1587.
147. Deol P., Khuller G.K. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim. Biophys. Acta 1997, 1334:161-172.
148. Deol P., Khuller G.K., Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob. Agents Chemother. 1997, 41:1211-1214.
149. Vyas S.P., Kannan M.E., Jain S., Mishra V., Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int. J. Pharm. 2004, 269:37-49.
150. Vyas S.P., Quraishi S., Gupta S., Jaganathan K.S. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int. J. Pharm. 2005, 296:12-25.
151. Wijagkanalan W., Higuchi Y., Kawakami S., Teshima M., Sasaki H., Hashida M. Enhanced anti-inflammation of inhaled dexamethasone palmitate using mannosylated liposomes in an endotoxin-induced lung inflammation model. Mol. Pharmacol. 2008, 74:1183-1192.
152. Wijagkanalan W., Kawakami S., Takenaga M., Igarashi R., Yamashita F., Hashida M. Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats. J. Control. Release 2008, 125:121-130.
153. Chono S., Kaneko K., Yamamoto E., Togami K., Morimoto M. Effect of surface-mannose modification on aerosolized liposomal delivery to alveolar macrophages. Drug Dev. Ind. Pharm. 2010, 36:102-107.
154. Gaspar M.M., Radomska A., Gobbo O.L., Bakowsky U., Radomska M.W., Ehrhardt C. Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats. J. Aerosol. Med. Pulm. Drug Deliv. 2011, 25:310-318.
155. Boman N.L., Mayer L.D., Cullis P.R. Optimization of the retention properties of vincristine in liposomal systems. Biochim. Biophys. Acta 1993, 1152:253-258.
156. Abraham S.A., Waterhouse D.N., Mayer L.D., Cullis P.R., Madden T.D., Bally M.B. The liposomal formulation of doxorubicin. Methods Enzymol. 2005, 391:71-97.
157. Johnston M.J., Semple S.C., Klimuk S.K., Edwards K., Eisenhardt M.L., Leng E.C., Karlsson G., Yanko D., Cullis P.R. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim. Biophys. Acta 2006, 1758:55-64.
158. Lasic D.D., Ceh B., Stuart M.C., Guo L., Frederik P.M., Barenholz Y. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim. Biophys. Acta 1995, 1239:145-156.
159. Mayer L.D., Bally M.B., Cullis P.R., Wilson S.L., Emerman J.T. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett. 1990, 53:183-190.
160. Jaafar-Maalej C., Elaissari A., Fessi H. Lipid-based carriers: manufacturing and applications for pulmonary route. Expert Opin. Drug Deliv. 2012, 9:1111-1127.
161. Rodríguez R.B., Xamaní M.S. Liposomes prepared by high-pressure homogenizers. Methods in Enzymology 2003, 367:28-46. Academic Press. N. Duzgunes (Ed.).
162. Yu B., Lee R.J., Lee L.J. Microfluidic methods for production of liposomes. Methods in Enzymology 2009, 465:129-141. Academic Press. N. Duzgunes (Ed.).
163. Mui B., Chow L., Hope M.J. Extrusion technique to generate liposomes of defined size. Methods in Enzymology 2003, 367:3-14. Academic Press. N. Duzgunes (Ed.).
164. Cipolla D., Redelmeir T., Eastman S., Bruinenberg P., Gonda I. Liposomes, niosomes and proniosomes - a critical update of their (commercial) development as inhaled products. Respiratory Drug Delivery Europe 2011 2011, 41-54. Davis Healthcare Int'l Publishing, IL. P.R. Byron, R.N. Dalby, J. Peart, J.D. Suman, S.J. Farr, P.M. Young (Eds.).
165. Bai S., Ahsan F. Inhalable liposomes of low molecular weight heparin for the treatment of venous thromboembolism. J. Pharm. Sci. 2010, 99:4554-4564.
166. Karathanasis E., Bhavane R., Annapragada A.V. Glucose-sensing pulmonary delivery of human insulin to the systemic circulation of rats. Int. J. Nanomedicine 2007, 2:501-513.
167. Huang Y.Y., Wang C.H. Pulmonary delivery of insulin by liposomal carriers. J. Control. Release 2006, 113:9-14.
168. Li Y., Mitra A.K. Effects of phospholipid chain length, concentration, charge, and vesicle size on pulmonary insulin absorption. Pharm. Res. 1996, 13:76-79.
169. Liu F.Y., Shao Z., Kildsig D.O., Mitra A.K. Pulmonary delivery of free and liposomal insulin. Pharm. Res. 1993, 10:228-232.
170. Mitra R., Pezron I., Li Y., Mitra A.K. Enhanced pulmonary delivery of insulin by lung lavage fluid and phospholipids. Int. J. Pharm. 2001, 217:25-31.
171. Hajos F., Stark B., Hensler S., Prassl R., Mosgoeller W. Inhalable liposomal formulation for vasoactive intestinal peptide. Int. J. Pharm. 2008, 357:286-294.
172. Stark B., Andreae F., Mosgoeller W., Edetsberger M., Gaubitzer E., Koehler G., Prassl R. Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation. Eur. J. Pharm. Biopharm. 2008, 70:153-164.
173. Stark B., Debbage P., Andreae F., Mosgoeller W., Prassl R. Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery. Biochim. Biophys. Acta Biomembr. 2007, 1768:705-714.
174. Swaminathan J., Gobbo O.L., Tewes F., Healy A.M., Ehrhardt C. Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin. J. Aerosol Med. Pulm. Drug Deliv 2014, 27:1-11.
175. Kellaway I.W., Farr S.J. Liposomes as drug delivery systems to the lung. Adv. Drug Deliv. Rev. 1990, 5:149-161.
176. Taylor K.M.G., Farr S.J. Liposomes for drug delivery to the respiratory tract. Drug Dev. Ind. Pharm. 1993, 19:123-142.
177. Mihalko P.J., Schreier H., Abra R.M. Liposomes: a pulmonary perspective. Liposomes as Drug Carriers 1998, 679-694. John Wiley & Sons. G. Gregoriadis (Ed.).
178. Schreier H., Gonzalez-Rothi R.J., Stecenko A.A. Pulmonary delivery of liposomes. J. Control. Release 1993, 24:209-223.
179. Schreier H. Liposome aerosols. J. Liposome Res. 1992, 2:145-184.
180. Schreier H. Pulmonary delivery of liposomal drugs. J. Liposome Res. 1994, 4:229-238.
181. Taylor K.M., Taylor G., Kellaway I.W., Stevens J. The influence of liposomal encapsulation on sodium cromoglycate pharmacokinetics in man. Pharm. Res. 1989, 6:633-636.
182. Pettenazzo A., Jobe A., Ikegami M., Abra R., Hogue E., Mihalko P. Clearance of phosphatidylcholine and cholesterol from liposomes, liposomes loaded with metaproterenol, and rabbit surfactant from adult rabbit lungs. Am. Rev. Respir. Dis. 1989, 139:752-758.
183. Abra R.M., Mihalko P.J., Schreier H. The effect of lipid composition upon the encapsulation and in vitro leakage of metaproterenol sulfate from 0.2μm diameter, extruded, multilamellar liposomes. J. Control. Release 1990, 14:71-78.
184. Fielding R.M., Abra R.M. Factors affecting the release rate of terbutaline from liposome formulations after intratracheal instillation in the guinea pig. Pharm. Res. 1992, 9:220-223.
185. Juliano R.L., McCullough H.N. Controlled delivery of an antitumor drug: localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system. J. Pharmacol. Exp. Ther. 1980, 214:381-387.
186. McCullough H.N., Juliano R.L. Organ-selective action of an antitumor drug: pharmacologic studies of liposome-encapsulated beta-cytosine arabinoside administered via the respiratory system of the rat. J. Natl. Cancer Inst. 1979, 63:727-731.
187. Debs R.J., Straubinger R.M., Brunette E.N., Lin J.M., Lin E.J., Montgomery A.B., Friend D.S., Papahadjopoulos D.P. Selective enhancement of pentamidine uptake in the lung by aerosolization and delivery in liposomes. Am. Rev. Respir. Dis. 1987, 135:731-737.
188. Padmanabhan R.V., Gudapaty R., Liener I.E., Schwartz B.A., Hoidal J.R. Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase. Am. Rev. Respir. Dis. 1985, 132:164-167.
189. Thibeault D.W., Rezaiekhaligh M., Mabry S., Beringer T. Prevention of chronic pulmonary oxygen toxicity in young rats with liposome-encapsulated catalase administered intratracheally. Pediatr. Pulmonol. 1991, 11:318-327.
190. Tousignant J.D., Gates A.L., Ingram L.A., Johnson C.L., Nietupski J.B., Cheng S.H., Eastman S.J., Scheule R.K. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum. Gene Ther. 2000, 11:2493-2513.
191. Tousignant J.D., Zhao H., Yew N.S., Cheng S.H., Eastman S.J., Scheule R.K. DNA sequences in cationic lipid:pDNA-mediated systemic toxicities. Hum. Gene Ther. 2003, 14:203-214.
192. Wittgen B.P., Kunst P.W., Perkins W.R., Lee J.K., Postmus P.E. Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J. Aerosol Med. 2006, 19:385-391.
193. Wittgen B.P., Kunst P.W., van der Born K., van Wijk A.W., Perkins W., Pilkiewicz F.G., Perez-Soler R., Nicholson S., Peters G.J., Postmus P.E. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin. Cancer Res. 2007, 13:2414-2421.
194. Behr J., Zimmermann G., Baumgartner R., Leuchte H., Neurohr C., Brand P., Herpich C., Sommerer K., Seitz J., Menges G., Tillmanns S., Keller M. Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. J. Aerosol Med. Pulm. Drug Deliv. 2009, 22:121-130.
195. Monforte V., Lopez-Sanchez A., Zurbano F., Ussetti P., Sole A., Casals C., Cifrian J., de Pablos A., Bravo C., Roman A. Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant. J. Heart Lung Transplant. 2013, 32:313-319.
196. Monforte V., Ussetti P., Gavalda J., Bravo C., Laporta R., Len O., Garcia-Gallo C.L., Tenorio L., Sole J., Roman A. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J. Heart Lung Transplant. 2010, 29:523-530.
197. Monforte V., Ussetti P., Lopez R., Gavalda J., Bravo C., de Pablo A., Pou L., Pahissa A., Morell F., Roman A. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J. Heart Lung Transplant. 2009, 28:170-175.
198. Slobbe L., Boersma E., Rijnders B.J. Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: data from a randomized placebo-controlled trial. Pulm. Pharmacol Ther. 2008, 21:855-859.
199. Weers J., Metzheiser B., Taylor G., Warren S., Meers P., Perkins W.R. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J. Aerosol Med. Pulm. Drug Deliv. 2009, 22:131-138.
200. Meers P., Neville M., Malinin V., Scotto A.W., Sardaryan G., Kurumunda R., Mackinson C., James G., Fisher S., Perkins W.R. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemother. 2008, 61:859-868.
201. Clancy J.P., Dupont L., Konstan M.W., Billings J., Fustik S., Goss C.H., Lymp J., Minic P., Quittner A.L., Rubenstein R.C., Young K.R., Saiman L., Burns J.L., Govan J.R.W., Ramsey B., Gupta R. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013, 68:818-825.
202. Clancy J.P., Minic P., Dupont L., Goss C., Quittner A., Lymp J., Burns J., Govan J., Ramsey B., Gupta R. Full analyses of data from two phase II blinded and placebo-controlled studies of nebulized liposomal amikacin for inhalation (Arikace™) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. Pediatr. Pulmonol. 2010, (Suppl. 33):299.
203. Okusanya O.O., Bhavnani S.M., Hammel J., Minic P., Dupont L.J., Forrest A., Mulder G.J., Mackinson C., Ambrose P.G., Gupta R. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob. Agents Chemother. 2009, 53:3847-3854.
204. Bilton D., Pressler T., Fajac I., et al. Phase 3 efficacy and safety data from randomized multicenter study of liposomal amikacin for inhalation (ARIKACE) compared with TOBI in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa. Pediatr. Pulmonol. 2013, 48:207-453.
205. Bruinenberg P., Blanchard J.D., Cipolla D.C., Dayton F., Mudumba S., Gonda I. Inhaled liposomal ciprofloxacin: once a day management of respiratory infections. Respiratory Drug Delivery 2010 2010, 73-81. Davis Healthcare Int'l Publishing, IL. P.R. Byron, R.N. Dalby, J. Peart, J.D. Suman, S.J. Farr, P.M. Young (Eds.).
206. Bilton D., DeSoyza A., Haworth C., Bruinenberg P., Otulana B. Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum Pseudomonas aeruginosa density in non-CF bronchiectasis. ERS Annual Conference 2009, (#1362).
207. Bruinenberg P., Otulana B., Blanchard J., Cipolla D., Wilson J., Serisier D. Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in CF patients. 32nd Annual Cystic Fibrosis Conference 2009, (#196).
208. Bruinenberg P., Otulana B., Blanchard J., Morishige R., Cipolla D., Wilson J., Serisier D. The effect of once-a-day, inhaled liposomal ciprofloxacin hydrochloride for inhalation on bacterial density in cystic fibrosis patients with P. aeruginosa infection. Pediatr. Pulmonol. 2008, 43:401.
209. Bruinenberg P., Serisier D., Cipolla D., Blanchard J. Safety, tolerability, pharmacokinetics and antimicrobial activity of inhaled liposomal ciprofloxacin formulations in humans. Pediatr. Pulmonol. 2010, 45:354.
210. Bruinenberg P., Serisier D., Blanchard J., Cipolla D., Gonda I. Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. ERS Annual Congress 2010, (#5574).
211. Serisier D.J., Bilton D., De Soyza A., Thompson P.J., Kolbe J., Greville H.W., Cipolla D., Bruinenberg P., Gonda I. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013, 68:812-817.
212. Crommelin D.J.A., Storm G. Liposomes: from the bench to the bed. J. Liposome Res. 2003, 13:33-36.
213. Grit M., Crommelin D.J. Chemical stability of liposomes: implications for their physical stability. Chem. Phys. Lipids 1993, 64:3-18.
214. Muppidi K., Pumerantz A.S., Wang J., Betageri G. Development and stability studies of novel liposomal vancomycin formulations. ISRN Pharm. 2012, 2012. (#636743). 10.5402/2012/636743.
215. Grit M., Crommelin D.J. The effect of aging on the physical stability of liposome dispersions. Chem. Phys. Lipids 1992, 62:113-122.
216. Zuidam N.J., Gouw H.K., Barenholz Y., Crommelin D.J. Physical (in) stability of liposomes upon chemical hydrolysis: the role of lysophospholipids and fatty acids. Biochim. Biophys. Acta 1995, 1240:101-110.
217. Jensen G.M., Bunch T.H., Hu N., Eley C.G.S. Process development and quality control of injectable liposomal therapeutics. Liposme Technology 2007, 297-310. Informa healthcare, New York. G. Gregoriadis (Ed.).
218. Niven R.W., Carvajal T.M., Schreier H. Nebulization of liposomes. III. The effects of operating conditions and local environment. Pharm. Res. 1992, 9:515-520.
219. Niven R.W., Schreier H. Nebulization of liposomes. I. Effects of lipid composition. Pharm. Res. 1990, 7:1127-1133.
220. Niven R.W., Speer M., Schreier H. Nebulization of liposomes. II. The effects of size and modeling of solute release profiles. Pharm. Res. 1991, 8:217-221.
221. Taylor K.M.G., Taylor G., Kellaway I.W., Stevens J. The stability of liposomes to nebulisation. Int. J. Pharm. 1990, 58:57-61.
222. Cipolla D.C., Dayton F., Fulzele S., Gabatan E., Mudumba S., Yim D., Wu H., Zwolinski R. Inhaled liposomal ciprofloxacin: in vitro properties and aerosol performance. Respiratory Drug Delivery 2010 2010, 409-414. Davis Healthcare Int'l Publishing, IL. R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman, S.J. Farr, P.M. Young (Eds.).
223. Cipolla D., Wu H., Chan J., Chan H.K., Gonda I. Liposomal ciprofloxacin for inhalation retains integrity following nebulization. Respiratory Drug Delivery Europe 2013 2013, 237-242. Davis Healthcare Int'l Publishing, IL. R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman, S.J. Farr, P.M. Young (Eds.).
224. Finlay W.H., Wong J.P. Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin. Int. J. Pharm. 1998, 167:121-127.
225. Morimoto Y., Adachi Y. Pulmonary uptake of liposomal phosphatidylcholine upon intratracheal administration to rats. Chem. Pharm. Bull. 1982, 30:2248-2251.
226. Meisner D., Pringle J., Mezei M. Liposomal pulmonary drug delivery. I. In vivo disposition of atropine base in solution and liposomal form following endotracheal instillation to the rabbit lung. J. Microencapsul. 1989, 6:379-387.
227. Khanna C., Anderson P.M., Hasz D.E., Katsanis E., Neville M., Klausner J.S. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 1997, 79:1409-1421.
228. Khanna C., Hasz D.E., Klausner J.S., Anderson P.M. Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies. Clin. Cancer Res. 1996, 2:721-734.
229. Koshkina N.V., Knight V., Gilbert B.E., Golunski E., Roberts L., Waldrep J.C. Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO2-enriched air: pharmacokinetic studies. Cancer Chemother. Pharmacol. 2001, 47:451-456.
230. Koshkina N.V., Waldrep J.C., Roberts L.E., Golunski E., Melton S., Knight V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin. Cancer Res. 2001, 7:3258-3262.
231. Knight V., Koshkina N.V., Waldrep J.C., Giovanella B.C., Gilbert B.E. Anti-cancer effect of 9-nitrocamptothecin liposome aerosol on human cancer zenografts in nude mice. Respiratory Drug Delivery VI 1998, 355-358. Interpharm Press, IL. R.N. Dalby, P.R. Byron, S.J. Farr (Eds.).
232. Knight V., Koshkina N., Waldrep C., Giovanella B.C., Kleinerman E., Gilbert B. Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice. Trans. Am. Clin. Climatol. Assoc. 2000, 111:135-145.
233. Kaipel M., Wagner A., Wassermann E., Vorauer-Uhl K., Kellner R., Redl H., Katinger H., Ullrich R. Increased biological half-life of aerosolized liposomal recombinant human Cu/Zn superoxide dismutase in pigs. J. Aerosol Med. Pulm. Drug Deliv. 2008, 21:281-290.
234. Jurima-Romet M., Shek P.N. Lung uptake of liposome-entrapped glutathione after intratracheal administration. J. Pharm. Pharmacol. 1991, 43:6-10.
235. Poiani G.J., Greco M., Choe J.K., Fox J.D., Riley D.J. Liposome encapsulation improves the effect of antifibrotic agent in rat lung fibrosis. Am. J. Respir. Crit. Care Med. 1994, 150:1623-1627.
236. Suntres Z.E., Hepworth S.R., Shek P.N. Pulmonary uptake of liposome-associated alpha-tocopherol following intratracheal instillation in rats. J. Pharm. Pharmacol. 1993, 45:514-520.
237. Suntres Z.E., Hepworth S.R., Shek P.N. Protective effect of liposome-associated alpha-tocopherol against paraquat-induced acute lung toxicity. Biochem. Pharmacol. 1992, 44:1811-1818.
238. Suntres Z.E., Shek P.N. Prophylaxis against lipopolysaccharide-induced lung injuries by liposome-entrapped dexamethasone in rats. Biochem. Pharmacol. 2000, 59:1155-1161.
239. Ivanova V., Garbuzenko O.B., Reuhl K.R., Reimer D.C., Pozharov V.P., Minko T. Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. Eur. J. Pharm. Biopharm. 2013, 84:335-344.
240. Chougule M., Padhi B., Misra A. Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. Int. J. Nanomedicine 2007, 2:675-688.
241. McCalden T.A., Abra R.A., Mihalko P.J. Bronchodilator effects of some liposome formulations of metaproterenol sulfate in guinea pigs. Proc. West. Pharmacol. Soc. 1988, 31:129-132.
242. Martin F. Development of liposomes for aerosol delivery: recent preclinical and clinical results. J. Liposome Res. 1990, 1:407-429.
243. McCalden T.A., Abra R.M., Mihalko P.J. Bronchodilator efficacy of liposome formulations of metaproterenol sulfate in the anesthetized guinea pig. J. Liposome Res. 1989, 1:211-222.
244. Gonzalez-Rothi R.J., Suarez S., Hochhaus G., Schreier H., Lukyanov A., Derendorf H., Costa T.D. Pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm. Res. 1996, 13:1699-1703.
245. Suarez S., Gonzalez-Rothi R.J., Hochhaus G., Schreier H. Effect of dose and release rate on pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm. Res. 1998, 15:461-465.
246. O'Riordan T.G., Waldrep J.C., Abraham W.M., Mao Y., Sabater J.R., Sielczak M., Knight V. Delivery of nebulized budesonide liposomes to the respiratory tract of allergic sheep. J. Aerosol Med. 1997, 10:117-128.
247. Gibbons A., Padilla-Carlin D., Kelly C., Hickey A.J., Taggart C., McElvaney N.G., Cryan S.A. The effect of liposome encapsulation on the pharmacokinetics of recombinant secretory leukocyte protease inhibitor (rSLPI) therapy after local delivery to a guinea pig asthma model. Pharm. Res. 2011, 28:2233-2245.
248. Chen X., Huang W., Wong B.C., Yin L., Wong Y.F., Xu M., Yang Z. Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int. J. Nanomedicine 2012, 7:1139-1148.
249. Joshi M., Misra A. Disposition kinetics of ketotifen from liposomal dry powder for inhalation in rat lung. Clin. Exp. Pharmacol. Physiol. 2003, 30:153-156.
250. Wijagkanalan W., Kawakami S., Higuchi Y., Yamashita F., Hashida M. Intratracheally instilled mannosylated cationic liposome/NFkappaB decoy complexes for effective prevention of LPS-induced lung inflammation. J. Control. Release 2011, 149:42-50.
251. Schreier H., McNicol K.J., Ausborn M., Soucy D.M., Derendorf H., Stecenko A.A., Gonzalez-Rothi R.J. Pulmonary delivery of amikacin liposomes and acute liposome toxicity in the sheep. Int. J. Pharm. 1992, 87:183-193.
252. Omri A., Beaulac J., Bouhajib M., Montplaisir S., Sharkawi M., Lagace J. Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1994, 38:1090-1095.
253. Poyner E.A., Alpar H.O., Almeida A.J., Gamble M.D., Brown M.R.W. A comparative study on the pulmonary delivery of tobramycin encapsulated into liposomes and PLA microspheres following intravenous and endotracheal delivery. J. Control. Release 1995, 35:41-48.
254. Beaulac C., Clement-Major S., Hawari J., Lagace J. In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition. J. Microencapsul. 1997, 14:335-348.
255. Beaulac C., Clement-Major S., Hawari J., Lagace J. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob. Agents Chemother. 1996, 40:665-669.
256. Conley J., Yang H., Wilson T., Blasetti K., Di Ninno V., Schnell G., Wong J.P. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob. Agents Chemother. 1997, 41:1288-1292.
257. Wong J.P., Yang H., Blasetti K.L., Schnell G., Conley J., Schofield L.N. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J. Control. Release 2003, 92:265-273.
258. Yim D., Blanchard J.D., Mudumba S., Eastman S., Manda K., Redelmeier T., Farr S. The development of inhaled liposome-encapsulated ciprofloxacin to treat cystic fibrosis. Respiratory Drug Delivery 2006 2006, 425-428. Davis Healthcare Int'l Publishing, IL. R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman, S.J. Farr (Eds.).
259. Chono S., Tanino T., Seki T., Morimoto K. Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification. J. Pharm. Pharmacol. 2007, 59:75-80.
260. Chono S., Suzuki H., Togami K., Morimoto K. Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects. Drug Dev. Ind. Pharm. 2008, 34:1090-1096.
261. Chono S., Tanino T., Seki T., Morimoto K. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J. Control. Release 2008, 127:50-58.
262. Hamblin K.A., Blanchard J.D., Davies C., Harding S.V., Simpson A.J.H. Efficacy of inhaled liposome-encapsulated ciprofloxacin against Yersinis pestis. 19th Congress of the International Society of Aerosols in Medicine 2013, (O-042).
263. Pandey R., Sharma S., Khuller G.K. Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int. J. Antimicrob. Agents 2004, 24:93-94.
264. Pandey R., Sharma S., Khuller G.K. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis. Int. J. Antimicrob. Agents 2004, 23:414-415.
265. Smith S.M., Cheng Y.S., Born J., Lyons C.R. Aerosolized liposomal isoniazid formulation for the treatment of Mycobacterium tuberculosis. Respiratory Drug Delivery VII 2000, 605-606. Amy Davis, Raleigh, NC. R.N. Dalby, P.R. Byron, S.J. Farr, J. Peart (Eds.).
266. Gilbert B.E. Liposomal aerosols in the management of pulmonary infections. J. Aerosol Med. 1996, 9:111-122.
267. Lambros M.P., Bourne D.W., Abbas S.A., Johnson D.L. Disposition of aerosolized liposomal amphotericin B. J. Pharm. Sci. 1997, 86:1066-1069.
268. Ruijgrok E.J., Vulto A.G., Van Etten E.W. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats. J. Pharm. Pharmacol. 2000, 52:619-627.
269. Takazono T., Izumikawa K., Mihara T., Kosai K., Saijo T., Imamura Y., Miyazaki T., Seki M., Kakeya H., Yamamoto Y., Yanagihara K., Kohno S. Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 2009, 53:3508-3510.
270. Canonico A.E., Brigham K.L., Carmichael L.C., Plitman J.D., King G.A., Blackwell T.R., Christman J.W. Aerosol and intravenous transfection of human alpha 1-antitrypsin gene to lungs of rabbits. Am. J. Respir. Cell Mol. Biol. 1994, 10:24-29.
271. McLachlan G., Davidson D.J., Stevenson B.J., Dickinson P., Davidson-Smith H., Dorin J.R., Porteous D.J. Evaluation in vitro and in vivo of cationic liposome-expression construct complexes for cystic fibrosis gene therapy. Gene Ther. 1995, 2:614-622.
272. Griesenbach U., Chonn A., Cassady R., Hannam V., Ackerley C., Post M., Tanswell A.K., Olek K., O'Brodovich H., Tsui L.C. Comparison between intratracheal and intravenous administration of liposome-DNA complexes for cystic fibrosis lung gene therapy. Gene Ther. 1998, 5:181-188.
273. Pillai R., Petrak K., Blezinger P., Deshpande D., Florack V., Freimark B., Padmabandu G., Rolland A. Ultrasonic nebulization of cationic lipid-based gene delivery systems for airway administration. Pharm. Res. 1998, 15:1743-1747.
274. Densmore C.L., Giddings T.H., Waldrep J.C., Kinsey B.M., Knight V. Gene transfer by guanidinium-cholesterol: dioleoylphosphatidyl-ethanolamine liposome-DNA complexes in aerosol. J. Gen. Med. 1999, 1:251-264.
275. Wang W.J., Liao B., Zeng M., Zhu C., Fan X.M. The effects of aerosolized STAT1 antisense oligodeoxynucleotides on rat pulmonary fibrosis. Cell. Mol. Immunol. 2009, 6:51-59.
276. Bi R., Shao W., Wang Q., Zhang N. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J. Drug Target. 2008, 16:639-648.
277. Shahiwala A., Misra A. Pulmonary absorption of liposomal levonorgestrel. AAPS PharmSciTech 2004, 5:E13.
278. Gupta V., Gupta N., Shaik I.H., Mehvar R., McMurtry I.F., Oka M., Nozik-Grayck E., Komatsu M., Ahsan F. Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. J. Control. Release 2013, 167:189-199.
279. Shahiwala A., Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: a technical note. AAPS PharmSciTech 2005, 6:E482-E486.
280. Kuiper L., Ruijgrok E.J. A review on the clinical use of inhaled amphotericin B. J. Aerosol Med. Pulm. Drug Deliv. 2009, 22:213-227.
281. Vipond J., Hatch G.J., Norville I.H., Atkinson D.J., Bate S.R., Bewley K.R., Charlwood M., McLuckie G., Pitman J.K., Atkins T.P. Comparison of the protective efficacy of liposome-encapsulated ciprofloxacin and doxycycline in mice against an aerosol challenge of Coxiella burnetii. University of Southampton's Wessex Life Sciences Alliance Conference 2012.
282. Waldrep J.C., Arppe J., Jansa K.A., Knight V. High dose cyclosporin A and budesonide-liposome aerosols. Int. J. Pharm. 1997, 152:27-36.
283. Verschraegen C.F., Gilbert B.E., Huaringa A.J., Newman R., Harris N., Leyva F.J., Keus L., Campbell K., Nelson-Taylor T., Knight V. Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs. Ann. N. Y. Acad. Sci. 2000, 922:352-354.
284. Skubitz K.M., Anderson P.M. Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial. Anticancer Drugs 2000, 11:555-563.
285. Hung O.R., Sellers E.M., Kaplan H.L., Romach M.K. Phase 1B clinical trial of aeroslized liposome encapsulated fentanyl (Aerolef) 2004, American Society for, Clinical Pharmacology and Therapeutics, (PI-3).
286. O'Donnell A., Swarnakar R., Yashina L., Nikolova P., Marinov R., Waghray P., Melnik V., Lazic Z., Penev A., Dimakou K., Mitic-Milikic M., Kline I., Tino G., Bilton D., Gupta R. A placebo controlled study of liposomal amikacin for inhalation (ARIKACE™) nebulized once-daily in the treatment of bronchiectasis patients with chronic Pseudomonas aeruginosa lung infection. ERS Annual Congress. 2009, 129:1361.
287. Rooney S. Phospholipid composition, biosynthesis and secretion. Comp. Biol. Human Lung 1992, 1:511-544.
288. Bilton D., Serisier D.J., DeSoyza A.T., Wolfe R., Bruinenberg P. Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of Pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis. ERS Annual Congress. 2011, 241:1925.
289. Speiser P. Lipidnanopellets als Trägersystem für Arzneimittel zur peroralen Anwendung 1986, (EP 0167825 A2).
290. Lucks J.S., Müller R.H., König B. Solid lipid nanoparticles (SLN)-an alternative parenteral drug delivery system. Eur. J. Pharm. Biopharm. 1992, 38:33.
291. Muller R.H., Shegokar R., Keck C.M. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr. Drug Discov. Technol. 2011, 8:207-227.
292. Mehnert W., Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47:165-196.
293. Hagemann J.W. Thermal behavior and polymorphism of acylglycerides. Crystallization and Polymorphism of Fats and Fatty Acids 1988, 9-95. Marcel Dekker Inc, New York. N. Garti, K. Sato (Eds.).
294. Schoenitz M., Joseph S., Nitz A., Bunjes H., Scholl S. Controlled polymorphic transformation of continuously crystallized solid lipid nanoparticles in a microstructured device: a feasibility study. Eur. J. Pharm. Biopharm. 2014, 86:324-331. 10.1016/j.ejpb.2013.08.009.
295. zur Muhlen A., Schwarz C., Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 1998, 45:149-155.
296. Delmas T., Fraichard A., Bayle P.A., Texier I., Bardet M., Baudry J., Bibette J., Couffin A.C. Encapsulation and release behavior from lipid nanoparticles: model study with nile red fluorophore. J. Colloid Sci. Biotechnol. 2012, 1:16-25.
297. Chattopadhyay P., Shekunov B.Y., Yim D., Cipolla D., Boyd B., Farr S. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv. Drug Deliv. Rev. 2007, 59:444-453.
298. Olbrich C., Müller R.H. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int. J. Pharm. 1999, 180:31-39.
299. Dong X., Mumper R.J. The metabolism of fatty alcohols in lipid nanoparticles by alcohol dehydrogenase. Drug Dev. Ind. Pharm. 2006, 32:973-980.
300. Muller R.H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
301. Yoon G., Park J., Yoon I.-S. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery. J. Pharm. Investig. 2013, 43:353-362.
302. Shekunov B.Y., Chattopadhyay P., Seitzinger J., Huff R. Nanoparticles of poorly water-soluble drugs prepared by supercritical fluid extraction of emulsions. Pharm. Res. 2006, 23:196-204.
303. Chattopadhyay P., Huff R., Shekunov B.Y. Drug encapsulation using supercritical fluid extraction of emulsions. J. Pharm. Sci. 2006, 95:667-679.
304. Liu J., Gong T., Fu H., Wang C., Wang X., Chen Q., Zhang Q., He Q., Zhang Z. Solid lipid nanoparticles for pulmonary delivery of insulin. Int. J. Pharm. 2008, 356:333-344.
305. Cavalli R., Caputo O., Carlotti M.E., Trotta M., Scarnecchia C., Gasco M.R. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int. J. Pharm. 1997, 148:47-54.
306. Heiati H., Tawashi R., Phillips N.C. Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving, storage and lyophilization. J. Microencapsul. 1998, 15:173-184.
307. Nayak A.P., Tiyaboonchai W., Patankar S., Madhusudhan B., Souto E.B. Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment. Colloids Surf. B: Biointerfaces 2010, 81:263-273.
308. Pardeike J., Weber S., Haber T., Wagner J., Zarfl H.P., Plank H., Zimmer A. Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int. J. Pharm. 2011, 419:329-338.
309. Li Y.Z., Sun X., Gong T., Liu J., Zuo J., Zhang Z.R. Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. Pharm. Res. 2010, 27:1977-1986.
310. Bi R., Shao W., Wang Q., Zhang N. Solid lipid nanoparticles as insulin inhalation carriers for enhanced pulmonary delivery. J. Biomed. Nanotechnol. 2009, 5:84-92.
311. Sahay G., Querbes W., Alabi C., Eltoukhy A., Sarkar S., Zurenko C., Karagiannis E., Love K., Chen D., Zoncu R., Buganim Y., Schroeder A., Langer R., Anderson D.G. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat. Biotechnol. 2013, 31:653-658.
312. Videira M.A., Botelho M.F., Santos A.C., Gouveia L.F., de Lima J.J., Almeida A.J. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J. Drug Target. 2002, 10:607-613.
313. Videira M.A., Gano L., Santos C., Neves M., Almeida A.J. Lymphatic uptake of lipid nanoparticles following endotracheal administration. J. Microencapsul. 2006, 23:855-862.
314. Videira M., Almeida A.J., Fabra A. Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomedicine 2012, 8:1208-1215.
315. Jaafar-Maalej C., Andrieu V., Elaissari A., Fessi H. Beclomethasone-loaded lipidic nanocarriers for pulmonary drug delivery: preparation, characterization and in vitro drug release. J. Nanosci. Nanotechnol. 2011, 11:1841-1851.
316. Patlolla R.R., Chougule M., Patel A.R., Jackson T., Tata P.N., Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J. Control. Release 2010, 144:233-241.
317. Pandey R., Khuller G.K. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 2005, 85:227-234.
318. Hureaux J., Lagarce F., Gagnadoux F., Vecellio L., Clavreul A., Roger E., Kempf M., Racineux J.L., Diot P., Benoit J.P., Urban T. Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel. Eur. J. Pharm. Biopharm. 2009, 73:239-246.
319. Taratula O., Kuzmov A., Shah M., Garbuzenko O.B., Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. Control. Release 2013, 171:349-357.
320. Hu L., Jia Y., Ding W. Preparation and characterization of solid lipid nanoparticles loaded with epirubicin for pulmonary delivery. Pharmazie 2010, 65:585-587.
321. Dharmala K., Yoo J.W., Lee C.H. Development of chitosan-SLN microparticles for chemotherapy: in vitro approach through efflux-transporter modulation. J. Control. Release 2008, 131:190-197.
322. Olbrich C., Bakowsky U., Lehr C.M., Muller R.H., Kneuer C. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J. Control. Release 2001, 77:345-355.
323. Rudolph C., Schillinger U., Ortiz A., Tabatt K., Plank C., Muller R.H., Rosenecker J. Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm. Res. 2004, 21:1662-1669.
324. Choi S.H., Jin S.E., Lee M.K., Lim S.J., Park J.S., Kim B.G., Ahn W.S., Kim C.K. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur. J. Pharm. Biopharm. 2008, 68:545-554.
325. Zhang L., Gu F.X., Chan J.M., Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 2008, 83:761-769.
326. Nassimi M., Schleh C., Lauenstein H.D., Hussein R., Lubbers K., Pohlmann G., Switalla S., Sewald K., Muller M., Krug N., Muller-Goymann C.C., Braun A. Low cytotoxicity of solid lipid nanoparticles in in vitro and ex vivo lung models. Inhal. Toxicol. 2009, 21:104-109.
327. Duffin R., Tran L., Brown D., Stone V., Donaldson K. Proinflammogenic effects of low-toxicity and metal nanoparticles in vivo and in vitro: highlighting the role of particle surface area and surface reactivity. Inhal. Toxicol. 2007, 19:849-856.
328. Nassimi M., Schleh C., Lauenstein H.D., Hussein R., Hoymann H.G., Koch W., Pohlmann G., Krug N., Sewald K., Rittinghausen S., Braun A., Muller-Goymann C.C. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur. J. Pharm. Biopharm. 2010, 75:107-116.
329. Martin D.D., Budamagunta M.S., Ryan R.O., Voss J.C., Oda M.N. Apolipoprotein A-I assumes a "looped belt" conformation on reconstituted high density lipoprotein. J. Biol. Chem. 2006, 281:20418-20426.
330. Burgess B.L., Cavigiolio G., Fannucchi M.V., Illek B., Forte T.M., Oda M.N. A phospholipid-apolipoprotein A-I nanoparticle containing amphotericin B as a drug delivery platform with cell membrane protective properties. Int. J. Pharm. 2010, 399:148-155.
331. Janoff A.S., Carpenter-Green S., Weiner A.L., Seibold J., Weissmann G., Ostro M.J. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:6122-6126.
332. Barenholz Y. Doxil(R)-the first FDA-approved nano-drug: lessons learned. J. Control. Release 2012, 160:117-134.
333. Chrastina A., Massey K.A., Schnitzer J.E. Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip. Rev. Nanomedicine Nanobiotechnol. 2011, 3:421-437.
334. Sheridan C. Proof of concept for next-generation nanoparticle drugs in humans. Nat. Biotechnol. 2012, 30:471-473.
335. Narang A.S., Chang R.K., Hussain M.A. Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems. J. Pharm. Sci. 2013, 102:3867-3882.